1. The "Metabolically Healthy Obese"

3. Introduction/Overview

4. The Global Epidemic of Obesity

5. Obesity as a Risk Factor for a Range of Comorbid Conditions

6. Life Expectancy Decreases as BMI Increases

7. Who Are the Metabolically Healthy Obese?[a,b]

8. Pear-Shape vs Apple-Shape Body Fat Distribution

9. Phenotyping the "Metabolically Healthy Obese": Key Clinical Parameters

10. Clinical and Functional Characteristics: MHO vs MUO

11. Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass

12. Post-Hoc Analysis Look AHEAD: The Importance of ≥10% Weight Loss

13. Mechanisms of Food Intake Regulation

14. Weight Loss Is Difficult, as Is Prevention of Weight Regain

15. Change in Weight From Baseline: Clinical Trial Data on 3 Approved Agents

16. Orlistat-Induced Weight Loss and Maintenance at 1 Year

17. SCALE: Change in Body Weight (%), Liraglutide vs Placebo

18. Weight Loss From Baseline for the Modified-ITT-LOCF Population and the Completer Population: Naltrexone + Bupropion vs Placebo

19. Targeting Multiple Physiologic Pathways in Energy Hemostasis and Weight Gain

20. Weight Loss and Prevention of New Disease Onset: Results of the SOS Study

21. AACE/TOS/ASMBS Guidelines: Criteria for Bariatric Surgery Recommendation

22. Obesity Is an Independent Risk Factor for CVD

23. Look AHEAD Results: Incidence of Very-High-Risk Chronic Kidney Disease by Treatment Group

24. Summary and Conclusions

25. Abbreviations

26. Abbreviations (cont)